featured
Durvalumab, With or Without Tremelimumab, Plus Platinum–Etoposide vs Platinum–Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durvalumab, With or Without Tremelimumab, Plus Platinum-Etoposide Versus Platinum-Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): Updated Results From a Randomised, Controlled, Open-Label, Phase 3 Trial
Lancet Oncol 2020 Dec 04;[EPub Ahead of Print], JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, G Statsenko, MJ Hochmair, M Özgüroğlu, JH Ji, MC Garassino, O Voitko, A Poltoratskiy, S Ponce, F Verderame, L Havel, I Bondarenko, A Każarnowicz, G Losonczy, NV Conev, J Armstrong, N Byrne, P Thiyagarajah, H Jiang, L Paz-AresFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.